Results 1-5 of 5 for drugs segment:8795538

Ceisteanna Eile - Other Questions: Medicinal Products (18 Jan 2024)

Stephen Donnelly: ...to spend as much money as quickly as possible on its products. When I talk to people working within the service, the view is more nuanced. They say Ireland does quite well in accessing some drugs, and is well ahead of other European countries, but that it is not universal in terms of access to all medicines. To that end, the Deputy will be aware there was a Mazars report done some years...

Ceisteanna Eile - Other Questions: Medicinal Products (18 Jan 2024)

Stephen Donnelly: ...at a minimum we need to know where the medicine is in the process. There is going to be more transparency as well around the criteria that are used. For example, when we are considering orphan drugs, there are additional criteria used because they do not fit into the normal cost-benefit criteria that are used for the more mainstream drugs. Second, I have allocated funding for a sizeable...

Ceisteanna Eile - Other Questions: Medicinal Products (18 Jan 2024)

Bernard Durkan: 10. To ask the Minister for Health the extent to which new modern, effective and safe drugs can become available here once approved by the EU authorities; and if he will make a statement on the matter. [1817/24]

Ceisteanna Eile - Other Questions: Medicinal Products (18 Jan 2024)

Bernard Durkan: This question seeks to ascertain the extent to which new, effective and safe drugs are made available for use by Irish patients as soon as they become approved at EU level.

Ceisteanna Eile - Other Questions: Medicinal Products (18 Jan 2024)

Bernard Durkan: I thank the Minister for his reply. What is the extent to which references come from the pharmaceutical sector on the ready availability as soon as these drugs are made available? For instance, what might be the time lag between approval in the European Union and in this country? I accept that we are a smaller country but we are a member of the European Union. As a member of the Single...